ArticleHaematologica2019
Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.Journal of thrombosis and haemostasis : JTH · 2020Trial
- Immune-Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report.Clinical case reports · 2026Article
- MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies.Frontiers in medicine · 2026Review
- Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes.British journal of haematology · 2026Article
- Article
- Adalimumab-Induced Thrombocytopenia: A Case Report of Drug-Induced Thrombocytopenia.Case reports in hematology · 2025Article
- Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.Current issues in molecular biology · 2024Review
- Serum from half of patients with immune thrombocytopenia trigger macrophage phagocytosis of platelets.Blood advances · 2023Article
- Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia.Haematologica · 2022Article
- Anti-glycoprotein antibodies and sequestration pattern of indium-labeled platelets in immune thrombocytopenia.Blood advances · 2022Article
- Article
- Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia.Journal of clinical medicine · 2021Review
- Review
- Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management.Journal of clinical medicine · 2021Review
- Integrative Genomic Analysis Reveals Four Protein Biomarkers for Platelet Traits.Circulation research · 2020Article
- Anti-glycoprotein Ibα autoantibodies do not impair circulating thrombopoietin levels in immune thrombocytopenia patients.Haematologica · 2020Article
- A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia.Blood advances · 2020Article
- Is the mysterious platelet receptor GPV an unsuspected major target for platelet autoantibodies?Haematologica · 2019Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet autoantibody-induced platelet clearance represents a major pathomechanism in immune thrombocytopenia (ITP). There is growing evidence for clinical differences between anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib/IX mediated ITP. Glycoprotein V is a well characterized target antigen in Varicella-associated and drug-induced thrombocytopenia. We conducted a systematic study assessing the prevalence and functional capacity of autoantibodies against glycoprotein V. A total of 1140 patients were included. In one-third of patients, platelet-bound autoantibodies against glycoproteins Ib/IX, IIb/IIIa, or V were detected in a monoclonal antibody immobilization of platelet antigen assay; platelet-bound autoantiglycoprotein V was present in the majority of samples (222 out of 343, 64.7%). Investigation of patient sera revealed the presence of free autoantibodies against glycoprotein V in 13.5% of these patients by an indirect monoclonal antibody immobilization of platelet antigen assay, but in 39.6% by surface plasmon resonance technology. These antibodies showed significantly lower avidity (association/dissociation ratio 0.32±0.13
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.